Clinical Trial Update: A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating allogeneic natural killer cells with trastuzumab and pertuzumab for refractory metastatic HER2-positive breast cancer has been terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Allogeneic natural killer cells
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Breast Neoplasms | Phase 1 | Status: TERMINATED